Robustness, Reliability, Reproducibility
Our 3 R’s is the thin line we walk on the road of truth, this is of course essential when investigating a new drug. Whether it is to test the toxicity of a drug on healthy cells or cancer-killing capacity of a novel cancer drug, we will screen apoptotic and necrotic markers in real-time up to 72 hours after treatment. The next step is to assist with the critical experiments to provide the important understanding of the underlying mechanism of action and its downstream effects.
Apoptosis, Necrosis, and Viability of colon cancer cells in response to immunotherapy
Phosphorylation of Akt in cancer cells, in response to immunotherapy
Intracellular signaling cascade (ERK-pathway) inhibited by the MEK-inhibitor Trametinib in cancer cells. The phosphorylation of ERK is diminished in the cancer cell with increasing concentration of the drug.